Keyphrases
Older Adults
65%
Denmark
59%
Children with Cancer
53%
Radiotherapy
53%
Maintenance Therapy
50%
Pediatric
49%
Pediatric Patients
45%
Acute Lymphoblastic Leukemia
44%
Hodgkin Lymphoma
42%
Adult Cancer
42%
6-mercaptopurine (6-MP)
39%
Pediatric Soft Tissue Sarcomas
37%
Rhabdomyosarcoma
34%
Childhood Acute Lymphoblastic Leukemia
32%
Young Cancer Patients
28%
Thioguanine nucleotides
27%
Methotrexate
26%
Confidence Interval
25%
Childhood Cancer
24%
Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
23%
Cancer Predisposition Syndrome
22%
Deep Inspiration Breath Hold
22%
Group Experiences
22%
Late Effects
20%
DNA-TG
20%
Whole Genome Sequencing
20%
Preadolescent children
19%
Germ Cells
18%
Leukemia
18%
Service User Involvement
17%
Thiopurine Methyltransferase
16%
Classical Hodgkin Lymphoma
16%
Head-and-neck
16%
Register Study
16%
Hazard Ratio
16%
Thioguanine
15%
Response-adapted
15%
Liquid Formulation
15%
Treatment Recommendations
15%
Qualitative Evaluation
15%
Titration
15%
Smartphone App
15%
Nationwide Register Study
15%
Pharmacokinetics
15%
Event-free Survival
13%
Prednisone
13%
Health-related Quality of Life
13%
Years of Life Lost
13%
In Cancer
13%
Improved Survival
12%
Medicine and Dentistry
Pediatrics
100%
Malignant Neoplasm
97%
Adolescent
75%
Radiation Therapy
69%
Hodgkin's Lymphoma
57%
Rhabdomyosarcoma
48%
Soft Tissue Sarcoma
45%
Pediatrics Patient
42%
Disease
39%
Neoplasm
36%
Cohort Analysis
30%
Childhood Cancer
28%
Acute Lymphoblastic Leukemia
27%
Pediatric Cancer
25%
Classical Hodgkin Lymphoma
24%
Breathing
22%
Hazard Ratio
21%
Leukemia
20%
Late Effect
20%
Neck
18%
Health Care
16%
Quality of Life
16%
Metastatic Carcinoma
16%
Symptom
16%
Cancer Susceptibility
15%
Titrimetry
15%
Vincristine
14%
Prednisone
14%
Event Free Survival
12%
Overall Survival
12%
Whole Genome Sequencing
12%
Sarcoma
11%
Positron Emission Tomography
11%
Maintenance Therapy
10%
Cancer
10%
Group Therapy
10%
Arm
10%
Burkitt's Lymphoma
10%
Methotrexate
9%
Thiopurine Methyltransferase
9%
Central Nervous System Tumor
9%
Prognostic Factor
9%
Osteosarcoma
9%
Minimal Residual Disease
9%
Survival Rate
8%
Second Cancer
8%
Rare Tumor
8%
Doxorubicin
8%
Etoposide
8%
Positron Emission Tomography-Computed Tomography
8%
